In the last five years, immunomodulatory antibodies have revolutionized cancer immunotherapy. CD137, a member of the tumor necrosis factor receptor superfamily, Recently, clinical trials of combination therapies with agonistic anti-CD137 mAbs have been launched. In this review, we discuss the recent advances and clinical promise of agonistic anti-CD137 monoclonal antibody therapy.
Introduction
Antibody-based strategies to cancer treatment have dramatically advanced in the last 20 years (1) . Since rituximab was approved as the first monoclonal antibody (mAb) for the treatment of cancer in 1997 (2, 3) , several mAbs have become standard of care for the treatment of both solid tumors and hematologic malignancies ( Table 1) Author Manuscript Published OnlineFirst on April 23, 2015; DOI: 10.1158/1078-0432.CCR- described below (Fig. 1 ). In addition, the role of CD137 signaling has been studied in several autoimmune processes (16) , including rheumatoid arthritis, experimental autoimmune encephalomyelitis, and systemic lupus erythematosus. These studies showed significant protection against the autoimmune disorders. This dual immunoregulatory activity of CD137 offers the possibility to enhance antitumor activity without autoimmune side effects associated with immunotherapy approaches.
Co-stimulation through CD137 T cell
The immune response induced by anti-CD137 mAbs is mediated by both CD8 + and CD4 + T cells and is accompanied by a significant increase in tumor-selective cytolytic T-cell activity, including increased T cell proliferation, resistance to apoptosis, and increased interferon (IFN)γ secretion (16 + and CD8  + T cells, and induce IL-2 and IL-8 secretion by DCs and macrophages, leading to enhanced T cell proliferation and cytokine secretion (22).
Anti-CD137 therapy was ineffective in B6 mouse embryo C3 tumors, TC-1 lung carcinoma and B16.F10 melanoma models, when CTLs were depleted (23). In melanoma tumor models, anti-CD137 antibodies not only prevented activation-induced cell death, but also augmented CD8 + T cell proliferative potential and enhanced cytolytic activity against tumor cells (24). In addition, co-stimulation through CD137
and OX40 activates Akt to promote cell cycling through regulation of cyclins and cyclin-dependent kinases (25). 
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Urelumab (BMS-663513)
The NCT00309023 study was a first-in-human open-label, ascending, multidose Phase I−II trial conducted in patients with locally advanced or metastatic solid tumors (62) . In the dose-escalation phase of the study, patients were sequentially assigned to one of six dose cohorts (0.3-15 mg/kg) to receive urelumab once every 3 weeks. Eighty-three
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on Although the studies (NCT00351325, NCT00461110, NCT00803374) were terminated or withdrawn, low-dose therapies (<0.1 mg/kg) of urelumab in combination with approved mAbs are worthy of attention.
PF-05082566
Clinical trials of PF-05082566 are also on-going. NCT01307267 is an open-label, dose escalation study that was conducted in patients with advanced malignancies, and the preliminary data was reported (68) . Cohorts of 3-6 patients were enrolled initially using 
